{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=18", "query": { "condition": "Relapsed/ Refractory T-cell Malignancies", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 845, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:52:30.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00096096", "title": "Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-05-13", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096096" }, { "nct_id": "NCT00005641", "title": "Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "15 Years to 60 Years" }, "enrollment_count": null, "start_date": "1997-09", "completion_date": "2000-09", "has_results": false, "last_update_posted_date": "2012-12-11", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005641" }, { "nct_id": "NCT06285422", "title": "Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin's Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "SC262", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sana Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2024-04-18", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 3, "location_summary": "Kansas City, Kansas • Seattle, Washington", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06285422" }, { "nct_id": "NCT01363817", "title": "Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute T-cell", "Precursor T-Cell Lymphoblastic Lymphoma" ], "interventions": [ { "name": "BMS-906024", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-09-28", "completion_date": "2018-02-07", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363817" }, { "nct_id": "NCT05108623", "title": "A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "agenT-797", "type": "DRUG" }, { "name": "Approved ICIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MiNK Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2022-01-28", "completion_date": "2024-01-02", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05108623" }, { "nct_id": "NCT06508463", "title": "Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peripheral T Cell Lymphoma", "Relapsed Peripheral T-Cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Anaplastic Large Cell Lymphoma", "Mycosis Fungoides", "Relapsed Anaplastic Large Cell Lymphoma", "Relapsed Mycosis Fungoides" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2024-01-05", "completion_date": "2032-04-01", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06508463" }, { "nct_id": "NCT01129193", "title": "AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Prolymphocytic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Pharmacodynamic Studies", "type": "OTHER" }, { "name": "Fatigue Inventory", "type": "OTHER" }, { "name": "Pharmacogenomic studies", "type": "OTHER" }, { "name": "AR-42", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Amir Mortazavi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2010-05-04", "completion_date": "2017-01-07", "has_results": false, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129193" }, { "nct_id": "NCT05403450", "title": "A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Tolinapant", "type": "DRUG" }, { "name": "Decitabine + Cedazuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-02-22", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 6, "location_summary": "Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05403450" }, { "nct_id": "NCT00064090", "title": "3-AP and Cytarabine in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "triapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-03", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064090" }, { "nct_id": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2004-02", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-15T17:52:30.285Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080925" } ] }